Joseph L McDevitt1, Ravi N Srinivasa2, Anthony N Hage3, Jacob J Bundy4, Joseph J Gemmete4, Jeffrey Forris Beecham Chick5. 1. Department of Radiology, Division of Vascular and Interventional Radiology, The University of Texas Southwestern Medical Center, Dallas, TX, USA. 2. Department of Radiology, Division of Interventional Radiology, University of California, Los Angeles, Los Angeles, CA, USA. 3. Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA. 4. Department of Radiology, Division of Vascular and Interventional Radiology, University of Michigan Health System, Ann Arbor, MI, USA. 5. Cardiovascular and Interventional Radiology, Inova Alexandria Hospital, 4320 Seminary Road, Alexandria, VA, USA. jeffreychick@gmail.com.
Abstract
BACKGROUND: Endovascular stent reconstruction is the standard of care for chronic venous occlusive disease in adults, but it has not been reported in pediatric patients. OBJECTIVE: This study reports the technical success, complications, clinical outcomes, and stent patency of iliocaval stent reconstruction for chronic iliocaval thrombosis in pediatric patients. MATERIALS AND METHODS: Fourteen patients, 13 (93%) male with a mean age of 16.4 years (range: 8-20 years), underwent iliocaval stent reconstruction for chronic iliocaval thrombosis. The mean number of prothrombotic risk factors was 2.5 (range: 0-4), including 7 (50%) patients with inferior vena cava atresia. At initial presentation, the Clinical, Etiology, Anatomy, and Pathophysiology classification (CEAP) score was C3 in 2 (14%) patients, C4 in 11 (79%) patients, and C6 in 1 (7.1%) patient. Time course of presenting symptoms included chronic (>4 weeks) (n=7; 50%) and acute worsening of chronic symptoms (2-4 weeks) (n=7; 50%). Aspects of recanalization and reconstruction, stenting technical success, complications, clinical outcomes and stent patency were recorded. Clinical success was defined as a 1-point decrease in the CEAP. Primary, primary-assisted, and secondary patency were defined by Cardiovascular and Interventional Radiological Society of Europe guidelines. RESULTS: Most procedures employed three access sites (range: 2-4). Intravascular ultrasound was employed in 11 (79%) procedures. Blunt and sharp recanalization techniques were used in 12 (86%) and 2 (14%) patients, respectively. Stenting technical success was 100%. Two (14%) minor adverse events occurred and mean post-procedure hospitalization was 2.8 days (range: 1-8 days). Clinical success rates at 2 weeks, 6 months and 12 months were 85%, 82%, and 83%, respectively. At a mean final clinical follow-up of 88 months (range: 16-231 months), clinical success was 93%. Estimated 6- and 12-month primary stent patencies were 86% and 64%, respectively. Six- and 12-month primary-assisted and secondary stent patency rates were both 100%. CONCLUSION: Iliocaval stent reconstruction is an effective treatment for symptomatic chronic iliocaval thrombosis in pediatric patients with high rates of technical success, 6- and 12-month clinical success, and 6- and 12-month primary-assisted and secondary patency rates.
BACKGROUND: Endovascular stent reconstruction is the standard of care for chronic venous occlusive disease in adults, but it has not been reported in pediatric patients. OBJECTIVE: This study reports the technical success, complications, clinical outcomes, and stent patency of iliocaval stent reconstruction for chronic iliocaval thrombosis in pediatric patients. MATERIALS AND METHODS: Fourteen patients, 13 (93%) male with a mean age of 16.4 years (range: 8-20 years), underwent iliocaval stent reconstruction for chronic iliocaval thrombosis. The mean number of prothrombotic risk factors was 2.5 (range: 0-4), including 7 (50%) patients with inferior vena cava atresia. At initial presentation, the Clinical, Etiology, Anatomy, and Pathophysiology classification (CEAP) score was C3 in 2 (14%) patients, C4 in 11 (79%) patients, and C6 in 1 (7.1%) patient. Time course of presenting symptoms included chronic (>4 weeks) (n=7; 50%) and acute worsening of chronic symptoms (2-4 weeks) (n=7; 50%). Aspects of recanalization and reconstruction, stenting technical success, complications, clinical outcomes and stent patency were recorded. Clinical success was defined as a 1-point decrease in the CEAP. Primary, primary-assisted, and secondary patency were defined by Cardiovascular and Interventional Radiological Society of Europe guidelines. RESULTS: Most procedures employed three access sites (range: 2-4). Intravascular ultrasound was employed in 11 (79%) procedures. Blunt and sharp recanalization techniques were used in 12 (86%) and 2 (14%) patients, respectively. Stenting technical success was 100%. Two (14%) minor adverse events occurred and mean post-procedure hospitalization was 2.8 days (range: 1-8 days). Clinical success rates at 2 weeks, 6 months and 12 months were 85%, 82%, and 83%, respectively. At a mean final clinical follow-up of 88 months (range: 16-231 months), clinical success was 93%. Estimated 6- and 12-month primary stent patencies were 86% and 64%, respectively. Six- and 12-month primary-assisted and secondary stent patency rates were both 100%. CONCLUSION: Iliocaval stent reconstruction is an effective treatment for symptomatic chronic iliocaval thrombosis in pediatric patients with high rates of technical success, 6- and 12-month clinical success, and 6- and 12-month primary-assisted and secondary patency rates.
Authors: Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Omid Khalilzadeh; Mark O Baerlocher; Paul B Shyn; Bairbre L Connolly; A Michael Devane; Christopher S Morris; Alan M Cohen; Mehran Midia; Raymond H Thornton; Kathleen Gross; Drew M Caplin; Gunjan Aeron; Sanjay Misra; Nilesh H Patel; T Gregory Walker; Gloria Martinez-Salazar; James E Silberzweig; Boris Nikolic Journal: J Vasc Interv Radiol Date: 2017-07-27 Impact factor: 3.464
Authors: Suresh Vedantham; Akhilesh K Sista; Seth J Klein; Lina Nayak; Mahmood K Razavi; Sanjeeva P Kalva; Wael E Saad; Sean R Dariushnia; Drew M Caplin; Christine P Chao; Suvranu Ganguli; T Gregory Walker; Boris Nikolic Journal: J Vasc Interv Radiol Date: 2014-07-04 Impact factor: 3.464
Authors: Jeffrey Forris Beecham Chick; Alexandria Jo; J Matthew Meadows; Steven D Abramowitz; Minhaj S Khaja; Kyle J Cooper; David M Williams Journal: J Vasc Interv Radiol Date: 2017-05-18 Impact factor: 3.464
Authors: H Bjarnason; J R Kruse; D A Asinger; G K Nazarian; C A Dietz; M D Caldwell; N S Key; A T Hirsch; D W Hunter Journal: J Vasc Interv Radiol Date: 1997 May-Jun Impact factor: 3.464
Authors: Neil A Goldenberg; Brian Branchford; Michael Wang; Charles Ray; Janette D Durham; Marilyn J Manco-Johnson Journal: J Vasc Interv Radiol Date: 2011-01-08 Impact factor: 3.464
Authors: Suresh Vedantham; Thomas M Vesely; Naveen Parti; Michael D Darcy; Thomas K Pilgram; Gregorio A Sicard; Daniel Picus Journal: J Vasc Interv Radiol Date: 2003-07 Impact factor: 3.464
Authors: Andrew M Bakken; Clinton D Protack; Wael E Saad; David E Lee; David L Waldman; Mark G Davies Journal: J Vasc Surg Date: 2007-04 Impact factor: 4.268